Mutations of the gene for nucleophosmin (NPM1) are the most frequent genetic aberration in patients with acute myeloid leukemia (AML). The mechanism of leukemic transformation in this leukemia subtype is not fully understood, but aberrant cytoplasmic localization of mutated NPM (NPMmut) is widely considered as an important factor for leukemia manifestation. We analyzed the subcellular localization of three types of NPM with a C-terminal mutation (A, B and E). Genes for the individual NPM forms were fused with a gene for one of fluorescent protein variants in plasmids, which were transfected into three cell lines with different endogenous NPM expression. Subcellular localization of the fluorescent protein-labeled NPM was further correlated with the relative expression of all NPM forms. We confirmed a high cytoplasmic expression of NPMmutA and NPMmutB whereas a substantial fraction of NPMmutE was found to be localized in nucleoli. Moreover, we revealed that the localization of fluorescently labeled NPM is affected by the interaction between various forms of the protein.

Institute of Hematology and Blood Transfusion Prague 2 Czech Republic

See more in PubMed

Itahana K, Bhat KP, Jin A, Itahana Y, Hawke D, Kobayashi R, et al. Tumor suppressor ARF degrades B23, a nucleolar protein involved in ribosome biogenesis and cell proliferation. Mol Cell 2003. November;12(5):1151–1164. PubMed

Okuda M. The role of nucleophosmin in centrosome duplication. Oncogene 2002. September 9;21(40):6170–6174. 10.1038/sj.onc.1205708 PubMed DOI

Enomoto T, Lindstrom MS, Jin A, Ke H, Zhang Y. Essential role of the B23/NPM core domain in regulating ARF binding and B23 stability. J Biol Chem 2006. July 7;281(27):18463–18472. 10.1074/jbc.M602788200 PubMed DOI

Kurki S, Peltonen K, Laiho M. Nucleophosmin, HDM2 and p53: players in UV damage incited nucleolar stress response. Cell Cycle 2004. August;3(8):976–979. PubMed

Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF, et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005. December 1;106(12):3733–3739. 10.1182/blood-2005-06-2248 PubMed DOI

Grummitt CG, Townsley FM, Johnson CM, Warren AJ, Bycroft M. Structural consequences of nucleophosmin mutations in acute myeloid leukemia. J Biol Chem 2008. August 22;283(34):23326–23332. 10.1074/jbc.M801706200 PubMed DOI PMC

Federici L, Falini B. Nucleophosmin mutations in acute myeloid leukemia: a tale of protein unfolding and mislocalization. Protein Sci 2013. May;22(5):545–556. 10.1002/pro.2240 PubMed DOI PMC

Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood 2007. February 1;109(3):874–885. 10.1182/blood-2006-07-012252 PubMed DOI

Thiede C, Koch S, Creutzig E, Steudel C, Illmer T, Schaich M, et al. Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). Blood 2006. May 15;107(10):4011–4020. 10.1182/blood-2005-08-3167 PubMed DOI

Dohner K, Schlenk RF, Habdank M, Scholl C, Rucker FG, Corbacioglu A, et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005. December 1;106(12):3740–3746. 10.1182/blood-2005-05-2164 PubMed DOI

Verhaak RG, Goudswaard CS, van Putten W, Bijl MA, Sanders MA, Hugens W, et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005. December 1;106(12):3747–3754. 10.1182/blood-2005-05-2168 PubMed DOI

Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. N Engl J Med 2005. January 20;352(3):254–266. 10.1056/NEJMoa041974 PubMed DOI

Bolli N, Nicoletti I, De Marco MF, Bigerna B, Pucciarini A, Mannucci R, et al. Born to be exported: COOH-terminal nuclear export signals of different strength ensure cytoplasmic accumulation of nucleophosmin leukemic mutants. Cancer Res 2007. July 1;67(13):6230–6237. 10.1158/0008-5472.CAN-07-0273 PubMed DOI

Chou SH, Ko BS, Chiou JS, Hsu YC, Tsai MH, Chiu YC, et al. A knock-in Npm1 mutation in mice results in myeloproliferation and implies a perturbation in hematopoietic microenvironment. PLoS One 2012;7(11):e49769 10.1371/journal.pone.0049769 PubMed DOI PMC

Pastore F, Greif PA, Schneider S, Ksienzyk B, Mellert G, Zellmeier E, et al. The NPM1 mutation type has no impact on survival in cytogenetically normal AML. PLoS One 2014. October 9;9(10):e109759 10.1371/journal.pone.0109759 PubMed DOI PMC

Alpermann T, Haferlach C, Dicker F, Eder C, Kohlmann A, Kern W, et al. Evaluation Of Different NPM1 Mutations In AML Patients According To Clinical, Cytogenetic and Molecular Features and Impact On Outcome. Blood 2013;122(21):51.

Koh Y, Park J, Bae EK, Ahn KS, Kim I, Bang SM, et al. Non-A type nucleophosmin 1 gene mutation predicts poor clinical outcome in de novo adult acute myeloid leukemia: differential clinical importance of NPM1 mutation according to subtype. Int J Hematol 2009. July;90(1):1–5. 10.1007/s12185-009-0350-1 PubMed DOI

Braoudaki M, Papathanassiou C, Katsibardi K, Tourkadoni N, Karamolegou K, Tzortzatou-Stathopoulou F. The frequency of NPM1 mutations in childhood acute myeloid leukemia. J Hematol Oncol 2010. October 27;3:41 10.1186/1756-8722-3-41 PubMed DOI PMC

Falini B, Albiero E, Bolli N, De Marco MF, Madeo D, Martelli M, et al. Aberrant cytoplasmic expression of C-terminal-truncated NPM leukaemic mutant is dictated by tryptophans loss and a new NES motif. Leukemia 2007. September;21(9):2052–4; author reply 2054; discussion 2055–6. 10.1038/sj.leu.2404839 PubMed DOI

Mitrea DM, Grace CR, Buljan M, Yun MK, Pytel NJ, Satumba J, et al. Structural polymorphism in the N-terminal oligomerization domain of NPM1. Proc Natl Acad Sci U S A 2014. March 25;111(12):4466–4471. 10.1073/pnas.1321007111 PubMed DOI PMC

Herrera JE, Correia JJ, Jones AE, Olson MO. Sedimentation analyses of the salt- and divalent metal ion-induced oligomerization of nucleolar protein B23. Biochemistry 1996. February 27;35(8):2668–2673. 10.1021/bi9523320 PubMed DOI

Bertwistle D, Sugimoto M, Sherr CJ. Physical and functional interactions of the Arf tumor suppressor protein with nucleophosmin/B23. Mol Cell Biol 2004. February;24(3):985–996. 10.1128/MCB.24.3.985-996.2004 PubMed DOI PMC

Huang M, Thomas D, Li MX, Feng W, Chan SM, Majeti R, et al. Role of cysteine 288 in nucleophosmin cytoplasmic mutations: sensitization to toxicity induced by arsenic trioxide and bortezomib. Leukemia 2013. October;27(10):1970–1980. 10.1038/leu.2013.222 PubMed DOI

Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, et al. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood 2011. January 27;117(4):1109–1120. 10.1182/blood-2010-08-299990 PubMed DOI

Balusu R, Fiskus W, Rao R, Chong DG, Nalluri S, Mudunuru U, et al. Targeting levels or oligomerization of nucleophosmin 1 induces differentiation and loss of survival of human AML cells with mutant NPM1. Blood 2011. September 15;118(11):3096–3106. 10.1182/blood-2010-09-309674 PubMed DOI PMC

Brodska B, Holoubek A, Otevrelova P, Kuzelova K. Low-Dose Actinomycin-D Induces Redistribution of Wild-Type and Mutated Nucleophosmin Followed by Cell Death in Leukemic Cells. J Cell Biochem 2016. June;117(6):1319–1329. 10.1002/jcb.25420 PubMed DOI

Bolli N, De Marco MF, Martelli MP, Bigerna B, Pucciarini A, Rossi R, et al. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF. Leukemia 2009. March;23(3):501–509. 10.1038/leu.2008.326 PubMed DOI

Kuzelova K, Brodska B, Fuchs O, Dobrovolna M, Soukup P, Cetkovsky P. Altered HLA Class I Profile Associated with Type A/D Nucleophosmin Mutation Points to Possible Anti-Nucleophosmin Immune Response in Acute Myeloid Leukemia. PLoS One 2015. May 20;10(5):e0127637 10.1371/journal.pone.0127637 PubMed DOI PMC

Macville M, Schrock E, Padilla-Nash H, Keck C, Ghadimi BM, Zimonjic D, et al. Comprehensive and definitive molecular cytogenetic characterization of HeLa cells by spectral karyotyping. Cancer Res 1999. January 1;59(1):141–150. PubMed

Alpermann T, Schnittger S, Eder C, Dicker F, Meggendorfer M, Kern W, et al. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia. Haematologica 2016. February;101(2):e55–8. 10.3324/haematol.2015.133819 PubMed DOI PMC

Gruszka AM, Lavorgna S, Consalvo MI, Ottone T, Martinelli C, Cinquanta M, et al. A monoclonal antibody against mutated nucleophosmin 1 for the molecular diagnosis of acute myeloid leukemias. Blood 2010. September 23;116(12):2096–2102. 10.1182/blood-2010-01-266908 PubMed DOI

Schnittger S, Bacher U, Haferlach C, Alpermann T, Dicker F, Sundermann J, et al. Characterization of NPM1-mutated AML with a history of myelodysplastic syndromes or myeloproliferative neoplasms. Leukemia 2011. April;25(4):615–621. 10.1038/leu.2010.299 PubMed DOI

Falini B, Nicoletti I, Bolli N, Martelli MP, Liso A, Gorello P, et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007. April;92(4):519–532. PubMed

Falini B, Martelli MP, Bolli N, Bonasso R, Ghia E, Pallotta MT, et al. Immunohistochemistry predicts nucleophosmin (NPM) mutations in acute myeloid leukemia. Blood 2006. September 15;108(6):1999–2005. 10.1182/blood-2006-03-007013 PubMed DOI

Hingorani K, Szebeni A, Olson MO. Mapping the functional domains of nucleolar protein B23. J Biol Chem 2000. August 11;275(32):24451–24457. 10.1074/jbc.M003278200 PubMed DOI

Prinos P, Lacoste MC, Wong J, Bonneau AM, Georges E. Mutation of cysteine 21 inhibits nucleophosmin/B23 oligomerization and chaperone activity. Int J Biochem Mol Biol 2011;2(1):24–30. PubMed PMC

Bischof D, Pulford K, Mason DY, Morris SW. Role of the nucleophosmin (NPM) portion of the non-Hodgkin's lymphoma-associated NPM-anaplastic lymphoma kinase fusion protein in oncogenesis. Mol Cell Biol 1997. April;17(4):2312–2325. PubMed PMC

Grisendi S, Bernardi R, Rossi M, Cheng K, Khandker L, Manova K, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005. September 1;437(7055):147–153. 10.1038/nature03915 PubMed DOI

Rashid NU, Sperling AS, Bolli N, Wedge DC, Van Loo P, Tai YT, et al. Differential and limited expression of mutant alleles in multiple myeloma. Blood 2014. November 13;124(20):3110–3117. 10.1182/blood-2014-04-569327 PubMed DOI PMC

Liu Y, He P, Liu F, Shi L, Zhu H, Zhao J, et al. Prognostic significance of NPM1 mutations in acute myeloid leukemia: A meta-analysis. Mol Clin Oncol 2014. March;2(2):275–281. 10.3892/mco.2013.222 PubMed DOI PMC

AML-Related NPM Mutations Drive p53 Delocalization into the Cytoplasm with Possible Impact on p53-Dependent Stress Response

NSC348884 cytotoxicity is not mediated by inhibition of nucleophosmin oligomerization

PAK1, PAK1Δ15, and PAK2: similarities, differences and mutual interactions

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin